| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Productivity > The Profitability of the Canadian Furniture Industry |
|
Digg It - The Profitability of the Canadian Furniture Industry
The Canadian furniture industry’s profit performance – in relation to the profitability According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product in overall manufacturing – depends on the kind of financial indicators chosen. The two m ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in st commonly used profitability indicators are: – the rate of pre-tax profits to total a lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ssets (or rate of return on assets) – the rate of pre-tax profits to total revenues here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe (or pre-tax profit margin) The furniture industry’s rate of return on assets has exceed d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ed the same ratio among manufacturers in general in each year since 1997. In 2004 the ra ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc e among furniture manufacturers averaged 7.5%, well ahead of the 6.2% prevailing among m easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi anufacturers in general. The rate of return on assets moves in step with the general bu nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically iness cycle. In fact, the rate declined significantly from is peak level of 13.2% in the and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ boom year of 1999. Pre-tax profits as a rate of return on total sales among furniture ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi anufacturers exceeded the same ratio among manufacturers in general in 1999, 2001 and 20 ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a 02. However, the relative strength of furniture manufacturers with respect to this meas dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod re does no longer prevail at the present time. The rates of return on sales among furnit cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ure manufacturers were well below those of manufacturers in general throughout most of t tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen e 1990s and again in 2003 and 2004. The rate of return on sales – like the rate of retu t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel rn on assets – rises and falls with the stage of the business cycle both among manufactu ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ers in general and among furniture manufacturers. In the furniture industry the rate dec y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products lined from its peak of 7.4% in 1999 to a cyclical low in 2003, but rose again in 2004 to . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de 4.9%. With the growing competion from imports from low-cost countries, we fear that the elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip fiancial health of the Canadian furniture industry may deteriorate in the years to come tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Comparing Types of Trade Show Displays The Man Who Offered to Beat Me Up
|